Incyte Co. (NASDAQ:INCY) EVP Yao Wenqing sold 3,165 shares of Incyte stock in a transaction on Friday, November 29th. The stock was sold at an average price of $95.00, for a total value of $300,675.00. Following the transaction, the executive vice president now directly owns 98,473 shares of the company’s stock, valued at approximately $9,354,935. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Yao Wenqing also recently made the following trade(s):
- On Monday, December 2nd, Yao Wenqing sold 16,835 shares of Incyte stock. The stock was sold at an average price of $95.00, for a total transaction of $1,599,325.00.
- On Friday, November 1st, Yao Wenqing sold 7,960 shares of Incyte stock. The shares were sold at an average price of $85.00, for a total transaction of $676,600.00.
- On Tuesday, October 29th, Yao Wenqing sold 2,040 shares of Incyte stock. The shares were sold at an average price of $85.00, for a total transaction of $173,400.00.
INCY stock opened at $94.10 on Wednesday. The stock has a market capitalization of $20.28 billion, a P/E ratio of 114.76, a PEG ratio of 1.37 and a beta of 1.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.01 and a current ratio of 5.02. Incyte Co. has a one year low of $57.00 and a one year high of $95.36. The company has a 50 day moving average price of $85.04 and a two-hundred day moving average price of $81.63.
A number of equities analysts have issued reports on INCY shares. JMP Securities lifted their target price on shares of Incyte from $107.00 to $110.00 and gave the stock a “market outperform” rating in a research report on Monday, September 30th. ValuEngine lowered shares of Incyte from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 5th. BMO Capital Markets began coverage on shares of Incyte in a research note on Thursday, September 12th. They set a “market perform” rating and a $85.00 price objective for the company. Mizuho reissued a “buy” rating and set a $98.00 price objective on shares of Incyte in a research note on Wednesday, November 27th. Finally, BidaskClub upgraded Incyte from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $93.05.
Large investors have recently made changes to their positions in the company. Commonwealth Bank of Australia lifted its position in Incyte by 49.2% during the second quarter. Commonwealth Bank of Australia now owns 376 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 124 shares during the period. Pathstone Family Office LLC purchased a new stake in Incyte in the 2nd quarter valued at about $34,000. Captrust Financial Advisors purchased a new stake in Incyte in the 2nd quarter valued at about $35,000. Benjamin F. Edwards & Company Inc. increased its stake in shares of Incyte by 617.7% during the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 445 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 383 shares during the last quarter. Finally, First Manhattan Co. acquired a new position in shares of Incyte during the 2nd quarter valued at about $50,000. 91.10% of the stock is owned by institutional investors and hedge funds.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.
Featured Story: What is a Candlestick Chart?
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.